Journal Watch · Journal of Medicinal Chemistry · 2026

Design, Synthesis, and Preclinical Evaluation of Inhibitor-Based Radiotracers for Potential Application in Monitoring CDK4/6 Expression.

In summary, these findings demonstrate the potential of [<sup>68</sup>Ga]Ga-PY03 as a PET radiotracer to monitor the CDK4/6 expression in tumors.

Pan Y, Zhang X, Zhou B et al.Journal of Medicinal Chemistry3 min readPharma relevance 60/100

DOI: 10.1021/acs.jmedchem.5c03163PMID: 41575830Study type: research study

TL;DR

In summary, these findings demonstrate the potential of [<sup>68</sup>Ga]Ga-PY03 as a PET radiotracer to monitor the CDK4/6 expression in tumors.

Key findings

  • Micro-PET/CT imaging demonstrated its capability to detect CDK4/6-overexpressed tumors and dynamically monitor CDK4/6 expression post-therapeutic.
  • Importantly, [<sup>68</sup>Ga]Ga-PY03 also enabled quantitative assessment of CDK4/6 target occupancy, providing a potential tool for therapy response evaluation.
  • In summary, these findings demonstrate the potential of [<sup>68</sup>Ga]Ga-PY03 as a PET radiotracer to monitor the CDK4/6 expression in tumors.

What they did

Flexible linkers and functionalized amino acids were incorporated to optimize pharmacokinetic and targeting properties. Among eight radiotracers, [<sup>68</sup>Ga]Ga-PY03 showed superior pharmacological and pharmacokinetic properties, including high stability, strong CDK4/6 binding affinity and low nonspecific uptake.

Full abstract (original)

Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) are essential drivers of cell cycle progression and have been validated as important therapeutic targets in oncology. In this study, we report the design, synthesis, and preclinical validation of a series of novel radiotracers ([<sup>68</sup>Ga]Ga-PY01-[<sup>68</sup>Ga]Ga-PY08) based on the pharmacophore of CDK4/6 inhibitor ribociclib.

What they did: Flexible linkers and functionalized amino acids were incorporated to optimize pharmacokinetic and targeting properties. Among eight radiotracers, [<sup>68</sup>Ga]Ga-PY03 showed superior pharmacological and pharmacokinetic properties, including high stability, strong CDK4/6 binding affinity and low nonspecific uptake.

Results & conclusions: Micro-PET/CT imaging demonstrated its capability to detect CDK4/6-overexpressed tumors and dynamically monitor CDK4/6 expression post-therapeutic. Importantly, [<sup>68</sup>Ga]Ga-PY03 also enabled quantitative assessment of CDK4/6 target occupancy, providing a potential tool for therapy response evaluation. In summary, these findings demonstrate the potential of [<sup>68</sup>Ga]Ga-PY03 as a PET radiotracer to monitor the CDK4/6 expression in tumors.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c03163 · PubMed 41575830.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

In summary, these findings demonstrate the potential of [<sup>68</sup>Ga]Ga-PY03 as a PET radiotracer to monitor the CDK4/6 expression in tumors.

What type of study is this?

It is a research study, published in Journal of Medicinal Chemistry in 2026. Flexible linkers and functionalized amino acids were incorporated to optimize pharmacokinetic and targeting properties.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.5c03163. PubMed ID: 41575830. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Pan Y, Zhang X, Zhou B et al.. Design, Synthesis, and Preclinical Evaluation of Inhibitor-Based Radiotracers for Potential Application in Monitoring CDK4/6 Expression.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.5c03163.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/design-synthesis-and-preclinical-evaluation-of-inhibitor-based-radiotrac-c03163/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides